Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30900
Title: | Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. | Austin Authors: | DiIorio, Michael;Kennedy, Kevin;Liew, Jean W;Putman, Michael S;Sirotich, Emily;Sattui, Sebastian E;Foster, Gary;Harrison, Carly;Larché, Maggie J;Levine, Mitchell;Moni, Tarin T;Thabane, Lehana;Bhana, Suleman;Costello, Wendy;Grainger, Rebecca;Machado, Pedro M;Robinson, Philip C;Sufka, Paul;Wallace, Zachary S;Yazdany, Jinoos;Gore-Massy, Monique;Howard, Richard A;Kodhek, More A;Lalonde, Nadine;Tomasella, Laura-Ann;Wallace, John;Akpabio, Akpabio;Alpízar-Rodríguez, Deshiré;Beesley, Richard P;Berenbaum, Francis;Bulina, Inita;Chock, Eugenia Yupei;Conway, Richard;Duarte-García, Alí;Duff, Eimear;Gheita, Tamer A;Graef, Elizabeth R;Hsieh, Evelyn;El Kibbi, Lina;Liew, David F L ;Lo, Chieh;Nudel, Michal;Singh, Aman Dev;Singh, Jasvinder A;Singh, Namrata;Ugarte-Gil, Manuel F;Hausmann, Jonathan S;Simard, Julia F;Sparks, Jeffrey A | Affiliation: | Department of Medicine, Clinical Epidemiology Unit, Sweden.. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA Medicine, Harvard Medical School, Boston, Massachusetts, USA Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA LupusChat, New York, New York, USA Rheumatology, Crystal Run Healthcare, Middletown, New York, USA Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA jsparks@bwh.harvard.edu.. Medicine, Harvard Medical School, Boston, Massachusetts, USA Rheumatology, Autoinflammatory UK, Edinburgh, UK Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia Rheumatology Clinical Pharmacology and Therapeutics MRC Centre for Neuromuscular Diseases, University College London, London, UK Rheumatology, University College London Centre for Rheumatology, London, UK Juvenile Arthritis Research, European Network for Childhood Arthritis (ENCA), Tonbridge, UK Rheumatology, HealthPartners, St Paul, Minnesota, USA Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA Medicine/Rheumatology, University of California, San Francisco, California, USA Lupus Foundation of America Inc, Washington, District of Columbia, USA Spondylitis Association of America, Van Nuys, California, USA Section of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA Rheumatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA Division of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA Rheumatology, VA Connecticut Healthcare System-West Haven Campus, West Haven, Connecticut, USA Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA Medicine Service, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA Medicine, Division of Rheumatology, University of Washington, Seattle, Washington, USA Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA Epidemiology and Population Health and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.. Medicine, McMaster University, Hamilton, Ontario, Canada.. Department of Health Research Methods, Evidence and Impact (HEI); Medicine, McMaster University, Hamilton, Ontario, Canada.. Divisions of Clinical Immunology and Allergy/Rheumatology, McMaster University Department of Medicine, Hamilton, Ontario, Canada.. Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.. Department of Biochemistry & Biomedical Sciences, McMaster University Faculty of Science, Hamilton, Ontario, Canada.. Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.. N/A, Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.. Department of Medicine, University of Otago Wellington, Wellington, New Zealand.. Lupus Foundation of Kenya, Nairobi, Kenya.. Patient Board, Covid-19 Global Rheumatology Alliance, London, Ontario, Canada.. Arthritis Kids South Africa, Johannesburg, South Africa.. Internal Medicine, University of Uyo Teaching Hospital, Uyo, Nigeria.. Research Unit, Mexican College of Rheumatology, Coyoacan, Mexico.. Rheumatology, Sorbonne Université, Paris, France.. Rheumatology, Paul Stradins Clinical University Hospital, Riga, Latvia.. Department of Rheumatology, Saint James's Hospital, Dublin, Ireland.. Rheumatology, Saint James's Hospital, Dublin, Ireland.. Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt.. Internal Medicine Department, Division of Rheumatology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia.. Rheumatology, I-Shou University College of Medicine, Yanchau Sheng, Taiwan.. N/A, The Israeli Association for RMDs patients "Mifrakim Tz'eirim", Haifa, Israel.. Department of Community Medicine, Government Medical College Amritsar, Amritsar, Punjab, India.. Rajindra Hospital Patiala, Patiala, Punjab, India.. School of Medicine, Universidad Cientifica del Sur, Lima, Peru.. Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.. |
Issue Date: | Sep-2022 | Publication information: | RMD open 2022; 8(2): e002587 | Abstract: | We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30900 | DOI: | 10.1136/rmdopen-2022-002587 | ORCID: | http://orcid.org/0000-0001-8230-091X http://orcid.org/0000-0001-9699-4000 http://orcid.org/0000-0002-7087-8543 http://orcid.org/0000-0002-3945-6828 http://orcid.org/0000-0002-8411-7972 http://orcid.org/0000-0002-3156-3418 http://orcid.org/0000-0002-4920-6494 http://orcid.org/0000-0002-6930-0517 http://orcid.org/0000-0001-8252-7815 http://orcid.org/0000-0003-1679-9745 http://orcid.org/0000-0001-8451-8883 http://orcid.org/0000-0003-3485-0006 http://orcid.org/0000-0003-1728-1999 http://orcid.org/0000-0003-0786-8788 http://orcid.org/0000-0001-5735-9856 http://orcid.org/0000-0002-5556-4618 |
Journal: | RMD open | PubMed URL: | 36104117 | Type: | Journal Article | Subjects: | COVID-19 inflammation patient reported outcome measures vaccination |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.